Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AmgenCHIX:AMGD 88 3-Year Dividend Growth Rate is 7.10% as of Mar. 2026, which is 43% below its 10-year median of 12.40. GuruFocus rates CHIX:AMGD with a GF Score™ of 88/100 and a GF Value™ of €261.88 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 352 Drug Manufacturers companies, Amgen ranks worse than 52.56% on this metric.
The historical rank and industry rank for Amgen's 3-Year Dividend Growth Rate or its related term are showing as below:
CHIX:AMGd'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 7.1 Med: 12.4 Max: 63.3
Current: 7.1
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Amgen was 63.30% per year. The lowest was 7.10% per year. And the median was 12.40% per year.
CHIX:AMGd's 3-Year Dividend Growth Rate is ranked worse than 52.56% of 352
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs CHIX:AMGd: 7.10
During the past 12 months, Amgen's average Dividends Per Share Growth Rate was 5.80% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 8.40% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 11.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest Dividend Payout Ratio of Amgen was 0.46. The lowest was 0.34. And the median was 0.40.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Amgen Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 2.520000
2026-05-15
2026-05-15
2026-06-05
Cash Dividend
quarterly
USD:EUR 0.856000
USD 2.520000
2026-02-13
2026-02-13
2026-03-06
Cash Dividend
quarterly
USD:EUR 0.846000
USD 2.380000
2025-11-21
2025-11-21
2025-12-12
Cash Dividend
quarterly
USD:EUR 0.865000
USD 2.380000
2025-08-22
2025-08-22
2025-09-12
Cash Dividend
quarterly
USD:EUR 0.859000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Amgen's Dividend Yield (%) for Today is calculated as
Current Share Price is €285.00.
Amgen's Dividends per Share for the trailing twelve months (TTM) ended in Today is €8.39216.
During the past 13 years, the highest Dividend Yield of Amgen was 3.72%. The lowest was 2.05%. And the median was 2.78%.
Warning Sign:
Amgen Inc stock Dividend Yield % is close to 5-year low.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen 3-Year Dividend Growth Rate Related Terms>
CHIX:AMGD vs GILD, PFE, BMY: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Amgen's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Amgen's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 7.10% mean?
Amgen (CHIX:AMGD) has a 3-Year Dividend Growth Rate of 7.10% as of Mar. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Amgen and its competitors. This is 43% below median its historical median of 12.40. Over the past decade, Amgen's 3-Year Dividend Growth Rate has ranged from 7.10 to 63.30. According to the industry distribution chart, Amgen ranks #185 out of 352 companies in the Drug Manufacturers industry, placing it in the top 52.6%.
Is Amgen's 3-Year Dividend Growth Rate too high?
Amgen's current 3-Year Dividend Growth Rate of 7.10% is 43% below median its 10-year median of 12.40. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 63.30. The Drug Manufacturers industry median 3-Year Dividend Growth Rate is 7.70. Amgen's value of 7.10% is 7.8% below this industry median. Based on the distribution chart, Amgen ranks #185 out of 352 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's 3-Year Dividend Growth Rate compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #185 out of 352 companies for 3-Year Dividend Growth Rate. This places Amgen in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 7.70. Amgen's value of 7.10% is 7.8% below this benchmark. Historically, Amgen's own 3-Year Dividend Growth Rate has ranged from 7.10 to 63.30 over the past decade. While the company's 10-year median is 12.40 vs. the industry median of 7.70, Amgen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 352 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current 3-Year Dividend Growth Rate of 7.10% is 7.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current 3-Year Dividend Growth Rate is 7.10%, which is 43% below median its own 10-year median of 12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €261.88, compared to a current price of €285.00 — trading 8.8% above its estimated fair value. The current 3-Year Dividend Growth Rate is 7.10%, which is 43% below median its 10-year median of 12.40 and 7.8% below the Drug Manufacturers industry median of 7.70. Amgen's overall GF Score™ is 88/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current 3-Year Dividend Growth Rate is 7.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of €285.00 is trading 8.8% above its estimated GF Value™ of €261.88.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
3-Year Dividend Growth Rate: 7.10% (43% below median its 10-year median of 12.40)
GF Value™: €261.88 vs. price of €285.00 (8.8% above fair value)
Industry Position: 7.8% below the Drug Manufacturers median (#185 of 352)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
88GF Score
Get the complete analysis for CHIX:AMGD
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
